May 11, 2020 / 9:11 AM / 16 days ago

BRIEF-Themis Collaborates With ABL Europe To Manufacture SARS-CoV-2 Vaccine Candidate In France

May 11 (Reuters) - THEMIS BIOSCIENCE BV:

* THEMIS COLLABORATES WITH ABL EUROPE TO MANUFACTURE ITS SARS-COV-2 VACCINE CANDIDATE IN FRANCE

* COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONS HAS INVESTED AN INITIAL USD 4.9 MILLION FOR ITS DEVELOPMENT Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below